Patient Characteristics
Patient No. . | Age (yr) . | Sex (M/F) . | Disease Duration . | Stage . | WBC Count (× 109/L) . | Morphologic Features . | Serum Ig (mg/dL)* . | ||
---|---|---|---|---|---|---|---|---|---|
. | . | . | . | . | . | . | IgG . | IgM . | IgA . |
1 | 82 | M | 12 yr | II | 77 | Typical CLL | 945 | 41 | 56 |
2 | 73 | M | 10 yr | 0 | 34 | Typical CLL | 900 | 105 | 117 |
3†‡ | 70 | F | 2 yr | III | 250 | Typical CLL | 1,040 | 21 | 34 |
4 | 51 | M | 2 yr | II | 38 | Typical CLL | 1,000 | 57 | 111 |
5 | 65 | F | 3 mo | 0 | 44 | Typical CLL | 662 | 33 | 22 |
6ρ | 67 | M | 3 yr | I | 40 | Typical CLL | 4,340 | 20 | 85 |
7 | 62 | M | 2 yr | I | 35 | Typical CLL | 1,490 | 34 | 202 |
8 | 70 | M | 2 mo | IV | 20 | Activated CLL/PL | 1,490 | 185 | 112 |
9 | 58 | M | 12 yr | 0 | 70 | Typical CLL | 513 | 72 | 110 |
10† | 76 | F | 6 yr | II | 30 | Typical CLL | 929 | 88 | 153 |
11 | 75 | F | 9 yr | IV | 70 | Typical CLL | 1,120 | 30 | 113 |
12 | 69 | M | 7 yr | IV | 110 | Typical CLL | 425 | 27 | 12 |
13 | 78 | M | 20 yr | 0 | 88 | Typical CLL | 936 | 22 | 67 |
14† | 75 | M | 11 yr | II | 12 | Typical CLL | 644 | 25 | 68 |
15 | 67 | M | 3 mo | I | 31 | Activated CLL/PL | 733 | 25 | 135 |
161-154 | 47 | M | 2 yr | 0 | 73 | Typical CLL | 1,130 | 82 | 266 |
17†‡ | 78 | F | III | 300 | Typical CLL | ||||
18#∥ | 50 | M | 7 yr | III | 27 | Typical CLL | 461 | 48 | 32 |
19† | 82 | M | 14 yr | III | 90 | PLL | 971 | 102 | 350 |
20† | 80 | F | II | 40 | Activated CLL/PL | 808 | 27 | 103 | |
21† | 89 | F | 9 yr | II | 45 | Activated CLL/PL | 378 | 17 | 29 |
22 | 80 | M | 9 yr | II | 57 | PLL | 897 | 38 | 61 |
231-167 | 70 | M | 4 yr | II | 35 | Activated CLL/PL | 852 | 28 | 125 |
Patient No. . | Age (yr) . | Sex (M/F) . | Disease Duration . | Stage . | WBC Count (× 109/L) . | Morphologic Features . | Serum Ig (mg/dL)* . | ||
---|---|---|---|---|---|---|---|---|---|
. | . | . | . | . | . | . | IgG . | IgM . | IgA . |
1 | 82 | M | 12 yr | II | 77 | Typical CLL | 945 | 41 | 56 |
2 | 73 | M | 10 yr | 0 | 34 | Typical CLL | 900 | 105 | 117 |
3†‡ | 70 | F | 2 yr | III | 250 | Typical CLL | 1,040 | 21 | 34 |
4 | 51 | M | 2 yr | II | 38 | Typical CLL | 1,000 | 57 | 111 |
5 | 65 | F | 3 mo | 0 | 44 | Typical CLL | 662 | 33 | 22 |
6ρ | 67 | M | 3 yr | I | 40 | Typical CLL | 4,340 | 20 | 85 |
7 | 62 | M | 2 yr | I | 35 | Typical CLL | 1,490 | 34 | 202 |
8 | 70 | M | 2 mo | IV | 20 | Activated CLL/PL | 1,490 | 185 | 112 |
9 | 58 | M | 12 yr | 0 | 70 | Typical CLL | 513 | 72 | 110 |
10† | 76 | F | 6 yr | II | 30 | Typical CLL | 929 | 88 | 153 |
11 | 75 | F | 9 yr | IV | 70 | Typical CLL | 1,120 | 30 | 113 |
12 | 69 | M | 7 yr | IV | 110 | Typical CLL | 425 | 27 | 12 |
13 | 78 | M | 20 yr | 0 | 88 | Typical CLL | 936 | 22 | 67 |
14† | 75 | M | 11 yr | II | 12 | Typical CLL | 644 | 25 | 68 |
15 | 67 | M | 3 mo | I | 31 | Activated CLL/PL | 733 | 25 | 135 |
161-154 | 47 | M | 2 yr | 0 | 73 | Typical CLL | 1,130 | 82 | 266 |
17†‡ | 78 | F | III | 300 | Typical CLL | ||||
18#∥ | 50 | M | 7 yr | III | 27 | Typical CLL | 461 | 48 | 32 |
19† | 82 | M | 14 yr | III | 90 | PLL | 971 | 102 | 350 |
20† | 80 | F | II | 40 | Activated CLL/PL | 808 | 27 | 103 | |
21† | 89 | F | 9 yr | II | 45 | Activated CLL/PL | 378 | 17 | 29 |
22 | 80 | M | 9 yr | II | 57 | PLL | 897 | 38 | 61 |
231-167 | 70 | M | 4 yr | II | 35 | Activated CLL/PL | 852 | 28 | 125 |
Abbreviations: WBC, white blood cell; AIHA, autoimmune hemolytic anemia; 2CDA, 2-chlorodeoxyadenosine.
Normal values: IgG 1,020 to 1,460; IgM 85 to 350; IgA 210 to 350.
Received treatment (prednisone, chlorambucil, or both).
Coombs+, AIHA.
ρ Patient also suffers from IgG κ myeloma.
Coombs+, no hemolysis.
IgA nephropathy.
Received treatment (2CDA).